Inhibrx Stock Performance
| INBX Stock | USD 14.86 0.78 5.54% |
The company retains a Market Volatility (i.e., Beta) of 0.64, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inhibrx's returns are expected to increase less than the market. However, during the bear market, the loss of holding Inhibrx is expected to be smaller as well. Inhibrx right now retains a risk of 3.14%. Please check out Inhibrx potential upside, and the relationship between the total risk alpha and kurtosis , to decide if Inhibrx will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 7.91 | Five Day Return 6.48 | Year To Date Return (60.06) | Ten Year Return (26.35) | All Time Return (26.35) |
1 | Acquisition by Mark Lappe of 26000 shares of Inhibrx at 15.29 subject to Rule 16b-3 | 09/06/2024 |
2 | Acquisition by Mark Lappe of 9500 shares of Inhibrx at 15.21 subject to Rule 16b-3 | 09/09/2024 |
3 | Acquisition by Mark Lappe of 8500 shares of Inhibrx at 15.19 subject to Rule 16b-3 | 09/10/2024 |
4 | Acquisition by Vuori Kristiina Md of 6457 shares of Inhibrx at 15.07 subject to Rule 16b-3 | 09/11/2024 |
5 | Acquisition by Mark Lappe of 26963 shares of Inhibrx at 15.05 subject to Rule 16b-3 | 09/12/2024 |
6 | Acquisition by Mark Lappe of 13037 shares of Inhibrx at 17.13 subject to Rule 16b-3 | 09/16/2024 |
7 | Acquisition by Vuori Kristiina Md of 6667 shares of Inhibrx at 15.0 subject to Rule 16b-3 | 10/03/2024 |
8 | Disposition of 15000 shares by Kayyem Jon Faiz of Inhibrx at 24.78 subject to Rule 16b-3 | 10/23/2024 |
9 | Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - BioSpace | 11/14/2024 |
10 | Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 | 11/19/2024 |
11 | Acquisition by Kayyem Jon Faiz of 18750 shares of Inhibrx at 14.1921 subject to Rule 16b-3 | 11/20/2024 |
| Begin Period Cash Flow | 273.9 M |
Inhibrx |
Inhibrx Relative Risk vs. Return Landscape
If you would invest 1,419 in Inhibrx on August 27, 2024 and sell it today you would lose (11.00) from holding Inhibrx or give up 0.78% of portfolio value over 90 days. Inhibrx is currently generating 0.036% in daily expected returns and assumes 3.139% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Inhibrx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inhibrx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibrx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inhibrx, and traders can use it to determine the average amount a Inhibrx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0115
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INBX |
Estimated Market Risk
| 3.14 actual daily | 27 73% of assets are more volatile |
Expected Return
| 0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Inhibrx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibrx by adding Inhibrx to a well-diversified portfolio.
Inhibrx Fundamentals Growth
Inhibrx Stock prices reflect investors' perceptions of the future prospects and financial health of Inhibrx, and Inhibrx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inhibrx Stock performance.
| Return On Equity | -20.31 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | 1,020 % | ||||
| Current Valuation | 9.32 M | ||||
| Shares Outstanding | 14.48 M | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 120.82 X | ||||
| Revenue | 1.8 M | ||||
| Gross Profit | (107.99 M) | ||||
| EBITDA | (206.69 M) | ||||
| Net Income | (241.36 M) | ||||
| Cash And Equivalents | 176.38 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 210.14 M | ||||
| Debt To Equity | 4.22 % | ||||
| Current Ratio | 7.51 X | ||||
| Book Value Per Share | 15.15 X | ||||
| Cash Flow From Operations | (193.31 M) | ||||
| Earnings Per Share | 119.39 X | ||||
| Market Capitalization | 203.82 M | ||||
| Total Asset | 307.89 M | ||||
| Retained Earnings | (613.73 M) | ||||
| Working Capital | 239.05 M | ||||
About Inhibrx Performance
Evaluating Inhibrx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Inhibrx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Inhibrx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.6 K | -3.4 K | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (5.55) | (5.27) |
Things to note about Inhibrx performance evaluation
Checking the ongoing alerts about Inhibrx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inhibrx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inhibrx had very high historical volatility over the last 90 days | |
| Inhibrx has a very high chance of going through financial distress in the upcoming years | |
| Inhibrx was previously known as INXB Old and was traded on NASDAQ Exchange under the symbol INXB. | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| Inhibrx currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Kayyem Jon Faiz of 34843 shares of Inhibrx at 14.2269 subject to Rule 16b-3 |
- Analyzing Inhibrx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inhibrx's stock is overvalued or undervalued compared to its peers.
- Examining Inhibrx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inhibrx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inhibrx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inhibrx's stock. These opinions can provide insight into Inhibrx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.